|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.025 GBX | -2.41% |
|
-0.49% | +21.48% |
| Apr. 29 | Immunovia Announces the Appointment of Lisa Fordas as Clinical Laboratory Director | CI |
| Apr. 02 | Immupharma jumps amid new IP strategy for P140 technology platform | AN |
ImmuPharma plc reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was GBP 0.069959 million. Net loss was GBP 0.847366 million compared to GBP 1.66 million a year ago.
Basic loss per share from continuing operations was GBP 0.0025 compared to GBP 0.0058 a year ago. Diluted loss per share from continuing operations was GBP 0.0025 compared to GBP 0.0058 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +21.48% | 10.8M | |
| +23.37% | 46.71B | |
| +48.83% | 41.8B | |
| -0.94% | 41.52B | |
| -5.86% | 29.55B | |
| +11.29% | 25.78B | |
| -20.92% | 19.26B | |
| +3.20% | 12.14B | |
| -2.67% | 12.08B | |
| +30.23% | 11.98B |
IMMUPHARMA PLC 